Genetic Risk Factors in Drug-Induced Liver Injury Due to Isoniazid-Containing Antituberculosis Drug Regimens.
Average rating
Cast your vote
You can rate an item by clicking the amount of stars they wish to award to this item.
When enough users have cast their vote on this item, the average rating will also be shown.
Star rating
Your vote was cast
Thank you for your feedback
Thank you for your feedback
Authors
Nicoletti, PaolaDevarbhavi, Harshad
Goel, Ashish
Venkatesan, Radha
Eapen, Chundamannil E
Grove, Jane I
Zafer, Samreen
Bjornsson, Einar
Lucena, M Isabel
Andrade, Raul J
Pirmohamed, Munir
Wadelius, Mia
Larrey, Dominique
Maitland-van der Zee, Anke-Hilse
Ibanez, Luisa
Watkins, Paul B
Daly, Ann K
Aithal, Guruprasad P
Issue Date
2020-11-01
Metadata
Show full item recordCitation
Nicoletti P, Devarbhavi H, Goel A, Venkatesan R, Eapen CE, Grove JI, et al. Genetic Risk Factors in Drug-Induced Liver Injury Due to Isoniazid-Containing Antituberculosis Drug Regimens. Clinical pharmacology and therapeutics. 2020.doi:10.1002/cpt.2100.Abstract
Drug-induced liver injury (DILI) is a complication of treatment with antituberculosis (TB) drugs, especially in isoniazid (INH)-containing regimens. To investigate genetic risk factors, we performed a genomewide association study (GWAS) involving anti-TB DILI cases (55 Indian and 70 European) and controls (1,199 Indian and 10,397 European). Most cases were treated with a standard anti-TB drug regimen; all received INH. We imputed single nucleotide polymorphism and HLA genotypes and performed trans-ethnic meta-analysis on GWAS and candidate gene genotypes. GWAS found one significant association (rs117491755) in Europeans only. For HLA, HLA-B*52:01 was significant (meta-analysis odds ratio (OR) 2.67, 95% confidence interval (CI) 1.63-4.37, P = 9.4 × 10-5 ). For N-acetyltransferase 2 (NAT2), NAT2*5 frequency was lower in cases (OR 0.69, 95% CI 0.57-0.83, P = 0.01). NAT2*6 and NAT2*7 were more common, with homozygotes for NAT2*6 and/or NAT2*7 enriched among cases (OR 1.89, 95% CI 0.84-4.22, P = 0.004). We conclude HLA genotype makes a small contribution to TB drug-related DILI and that the NAT2 contribution is complex, but consistent with previous reports when differences in the metabolic effect of NAT2*5 compared with those of NAT2*6 and NAT2*7 are considered.Description
To access publisher's full text version of this article, please click on the hyperlink in Additional Links field or click on the hyperlink at the top of the page marked DownloadAdditional Links
https://ascpt.onlinelibrary.wiley.com/doi/10.1002/cpt.2100Rights
© 2020 The Authors. Clinical Pharmacology & Therapeutics published by Wiley Periodicals LLC on behalf of American Society for Clinical Pharmacology and Therapeutics.ae974a485f413a2113503eed53cd6c53
10.1002/cpt.2100
Scopus Count
Collections
Related articles
- Polymorphisms of NAT2, CYP2E1, GST, and HLA related to drug-induced liver injury in indonesian tuberculosis patients.
- Authors: Perwitasari DA, Darmawan E, Mulyani UA, Vlies PV, Alffenaar JC, Atthobar J, Wilffert B
- Issue date: 2018 Oct-Dec
- Association and clinical utility of NAT2 in the prediction of isoniazid-induced liver injury in Singaporean patients.
- Authors: Chan SL, Chua APG, Aminkeng F, Chee CBE, Jin S, Loh M, Gan SH, Wang YT, Brunham LR
- Issue date: 2017
- The association between the NAT2 genetic polymorphisms and risk of DILI during anti-TB treatment: a systematic review and meta-analysis.
- Authors: Zhang M, Wang S, Wilffert B, Tong R, van Soolingen D, van den Hof S, Alffenaar JW
- Issue date: 2018 Dec
- Development of a prediction system for anti-tuberculosis drug-induced liver injury in Japanese patients.
- Authors: Mushiroda T, Yanai H, Yoshiyama T, Sasaki Y, Okumura M, Ogata H, Tokunaga K
- Issue date: 2016
- N-acetyltransferase 2 (NAT2) genotype as a risk factor for development of drug-induced liver injury relating to antituberculosis drug treatment in a mixed-ethnicity patient group.
- Authors: Ng CS, Hasnat A, Al Maruf A, Ahmed MU, Pirmohamed M, Day CP, Aithal GP, Daly AK
- Issue date: 2014 Sep